Strong trial results for orforglipron—a GLP-1 pill from market rival Eli Lilly—have also contributed to the declining share price for Novo. Before the release of Novo's CagriSema study results ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been ... Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin ...

Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...

Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...